A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2011
12/06/2011	US8071334 Preparation of soluble N-protein/truncated P-protein complexes of the paramyxoviridae family
12/06/2011	US8071333 Anti-integrin antibodies, compositions, methods and uses
12/06/2011	US8071323 Human monoclonal antibodies that bind human insulin like growth factors and their use
12/06/2011	US8071321 administering interferon-beta (IFN- beta) receptor agonist and tumor associated antigen to increase an immune response against the tumor cells
12/06/2011	US8071113 Immunogens; O-specific polysaccharide and DNA encoding O antigen biosynthesis
12/06/2011	US8071112 Compositions and methods of use of ORF-1358 from beta-hemolytic streptococcal strains
12/06/2011	US8071111 Virulence of Streptococci
12/06/2011	US8071109 VMP-like sequences of pathogenic Borrelia
12/06/2011	US8071108 Pestivirus mutant for use in a vaccine
12/06/2011	US8071107 Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins
12/06/2011	US8071104 Neovascular-targeted immunoconjugates
12/06/2011	US8071103 Pharmaceutical composition comprising a human GLP-1 mimetibody
12/06/2011	US8071102 Methods to clear meningitis causing agents using antibodies to peptides representing epitopic sites for bacterial and viral meningitis causing agents
12/06/2011	US8071101 Antibody therapy for treatment of diseases associated with gluten intolerance
12/06/2011	US8071100 Monoclonal antibodies that neutralize anthrax toxins
12/06/2011	US8071099 Anti-FLT3 antibodies
12/06/2011	US8071098 Method of preventing cerebral vasospasm with anti-HMGB1 antibody
12/06/2011	US8071097 Apoptotic anti-IgE antibodies
12/06/2011	US8071096 Anti-C5aR antibodies and uses thereof
12/06/2011	US8071095 Immunosuppressive polypeptides and nucleic acids
12/06/2011	US8071094 Anti-idiotypic antibody neutralizing the inhibitor activity of a factor VIII inhibitor antibody
12/06/2011	US8071093 Fully human anti-epidermal growth factor receptor antibodies
12/06/2011	US8071092 Methods of inhibiting B lymphocytes using antibodies to Neutrokine-alpha
12/06/2011	US8071087 Reovirus for the treatment of cellular proliferative disorders
12/06/2011	US8071084 Vaccine for protection against Shigella sonnei disease
12/06/2011	US8071074 e.g. (6,7-(dimethoxyquinazolin-4-yl)-(3-ethynylphenyl)-amine; epidermal growth factor receptor (EGF-R) antagonist, tyrosine kinase inhibitor; hypersecretion of mucus in lungs: chronic bronchitis, acute asthma, cystic fibrosis, bronchiectasis, chronic obstructive lung disease
12/06/2011	US8071072 Cytotoxicity mediation of cells evidencing surface expression of CD44
12/06/2011	CA2566299C Recombinant chemotactic antigen gene vaccine
12/06/2011	CA2512933C A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
12/06/2011	CA2510457C Hpv-16 and -18 l1 vlp vaccine
12/06/2011	CA2490693C Gene regulation in transgenic animals using a transposon-based vector
12/06/2011	CA2486759C Universal chimera bank
12/06/2011	CA2473163C Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
12/06/2011	CA2370867C Use of glucose-6-phosphate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds
12/06/2011	CA2328783C Human procalcitonin and the preparation and use thereof
12/06/2011	CA2305683C Immunogenic peptides from the hpv e7 protein
12/06/2011	CA2250164C Oncofetal antigen specific t-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific cd4, cd8 cytotoxic and suppressor t cells and interleukin-10
12/06/2011	CA2232563C Live vaccine carrier strains useful for high level expression of heterologous o-antigens from gram-negative pathogens and derivatives thereof for use as live vaccines
12/06/2011	CA2211039C Medicinal combination useful for in vivo exogenic transfection and expression
12/01/2011	WO2011150418A2 Compositions and methods for treating pathologies
12/01/2011	WO2011150392A1 Delivery of therapeutic agents to inflamed tissues using folate-targeted agents
12/01/2011	WO2011150284A2 Removal of serine proteases by treatment with finely divided silicon dioxide
12/01/2011	WO2011150281A2 A compositon for neurological or autoimmune diseases
12/01/2011	WO2011150279A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
12/01/2011	WO2011150264A2 Synthetic nanocarrier combination vaccines
12/01/2011	WO2011150249A1 Multivalent synthetic nanocarrier vaccines
12/01/2011	WO2011150235A1 Methods and reagents for treating autoimmune disorders and/or graft rejection
12/01/2011	WO2011150181A2 Compositions and methods for treating or inhibiting infection by francisella tularensis
12/01/2011	WO2011150127A2 Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells
12/01/2011	WO2011150061A1 Insulin-like growth factor 1 receptor binding peptides
12/01/2011	WO2011150008A1 Antibodies to human gdf8
12/01/2011	WO2011149999A2 Method for preparing antibodies having improved properties
12/01/2011	WO2011149955A2 Therapeutic method and composition
12/01/2011	WO2011149909A2 Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
12/01/2011	WO2011149778A1 Synthetic oligosaccharides for neisseria meningitis vaccine
12/01/2011	WO2011149493A1 Single -chain variable fragment anti-cd133 antibodies and uses thereof
12/01/2011	WO2011149461A1 Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
12/01/2011	WO2011149419A1 Vaccine against streptococcal infections based on recombinant proteins
12/01/2011	WO2011149389A1 An immunogenic composition for treatment of hepatitis c, a method for preparing the composition and use thereof for treating hepatitis c
12/01/2011	WO2011149134A1 Anticancer composition
12/01/2011	WO2011149099A1 Antigen peptide and use thereof
12/01/2011	WO2011149096A1 Insulin-resistance-improving drug
12/01/2011	WO2011149061A1 Composite body containing inactivated virus particle and use thereof
12/01/2011	WO2011149051A1 Antitumor t cell response enhancer
12/01/2011	WO2011149046A1 Therapeutic agent for pancreatic cancer
12/01/2011	WO2011148983A1 Induced malignant stem cells or pre-induction cancer stem cells capable of self-replication outside of an organism, production method for same, and practical application for same
12/01/2011	WO2011148382A1 An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
12/01/2011	WO2011148356A1 Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
12/01/2011	WO2011148147A1 Compositions and methods for treating disorders associated with atherosclerotic plaques
12/01/2011	WO2011147986A1 Monoclonal antibodies against her2
12/01/2011	WO2011147984A1 Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
12/01/2011	WO2011147982A2 Monoclonal antibodies against her2 epitope
12/01/2011	WO2011147975A1 Chimeric momp antigen, method and use
12/01/2011	WO2011147921A1 Stable multi-dose compositions comprising an antibody and a preservative
12/01/2011	WO2011147863A1 Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
12/01/2011	WO2011147834A1 Antibodies against cd19 and uses thereof
12/01/2011	WO2011147622A1 Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells
12/01/2011	WO2011147002A1 Porcine adenovirus 3-based prrsv vaccines
12/01/2011	WO2011123489A3 Anti-cd40 antibodies
12/01/2011	WO2011121556A3 Monoclonal antibody directed against the p17 protein of hiv, capable of neutralising the binding of p17 to the p17 receptor (p17r)
12/01/2011	WO2011112953A3 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
12/01/2011	WO2011091078A3 Antibody fc variants with enhanced complement activity
12/01/2011	WO2011090283A3 Composition containing inhibitors of the expression or activity of sh3rf2 for preventing or treating cancer
12/01/2011	WO2011086143A3 Liver targeting domain antibodies
12/01/2011	WO2011067672A3 Arranging interaction and back pressure chambers for microfluidization
12/01/2011	WO2011034604A3 Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
12/01/2011	US20110296545 Compositions and methods for treating or preventing conditions and diseases associated with mannheimia haemolytica
12/01/2011	US20110296544 Colon cancer targets and uses thereof
12/01/2011	US20110294986 Methods For Detecting Th1 Cells
12/01/2011	US20110294984 Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity
12/01/2011	US20110294146 Identification of Actinobacillus actinomycetemcomitans Antigens for Use in the Diagnosis, Treatment, and Monitoring of Periodontal Diseases
12/01/2011	US20110293733 Self-assembling nanoparticle drug delivery system
12/01/2011	US20110293723 Synthetic nanocarrier combination vaccines
12/01/2011	US20110293710 Immunomodulatory properties of lactobacillus strains
12/01/2011	US20110293704 Priming of an immune response
12/01/2011	US20110293701 Multivalent synthetic nanocarrier vaccines
12/01/2011	US20110293700 Nanocarrier compositions with uncoupled adjuvant
12/01/2011	US20110293697 HIV-1 Immunogenic Compositions
12/01/2011	US20110293665 Recombinant Der P 2 Expressed in Pichia Pastoris as a "Natural-Like" Allergen for Immunotherapy and Diagnostic Purposes
12/01/2011	US20110293664 Chlamydia antigens and uses thereof

1 ... 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 ... 1823